Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 39

1.

Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling.

Dickschen K, Eissing T, Mürdter T, Schwab M, Willmann S, Hempel G.

Springerplus. 2014 Jun 5;3:285. doi: 10.1186/2193-1801-3-285. eCollection 2014.

PMID:
24936398
[PubMed]
Free PMC Article
2.

Extraction of tamoxifen and its metabolites from formalin-fixed, paraffin-embedded tissues: an innovative quantitation method using liquid chromatography and tandem mass spectrometry.

Ng ES, Kangarloo SB, Konno M, Paterson A, Magliocco AM.

Cancer Chemother Pharmacol. 2014 Mar;73(3):475-84. doi: 10.1007/s00280-013-2346-z. Epub 2014 Jan 12.

PMID:
24414550
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites.

Jager NG, Koornstra RH, Vincent AD, van Schaik RH, Huitema AD, Korse TM, Schellens JH, Linn SC, Beijnen JH.

BMC Cancer. 2013 Dec 28;13:612. doi: 10.1186/1471-2407-13-612.

PMID:
24373320
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

In vitro human skin permeation of endoxifen: potential for local transdermal therapy for primary prevention and carcinoma in situ of the breast.

Lee O, Ivancic D, Chatterton RT Jr, Rademaker AW, Khan SA.

Breast Cancer (Dove Med Press). 2011 Jul 14;3:61-70. doi: 10.2147/BCTT.S20821. eCollection 2011.

PMID:
24367176
[PubMed]
Free PMC Article
5.

Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patients.

Fernández-Santander A, Gaibar M, Novillo A, Romero-Lorca A, Rubio M, Chicharro LM, Tejerina A, Bandrés F.

PLoS One. 2013 Jul 29;8(7):e70183. doi: 10.1371/journal.pone.0070183. Print 2013.

PMID:
23922954
[PubMed - in process]
Free PMC Article
6.

Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study.

Brooks JD, Teraoka SN, Malone KE, Haile RW, Bernstein L, Lynch CF, Mellemkjær L, Duggan DJ, Reiner AS, Concannon P, Schiermeyer K, Lewinger JP; WECARE Study Collaborative Group, Bernstein JL, Figueiredo JC.

Int J Mol Epidemiol Genet. 2013;4(1):35-48. Epub 2013 Mar 18.

PMID:
23565321
[PubMed]
Free PMC Article
7.

Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens.

Hawse JR, Subramaniam M, Cicek M, Wu X, Gingery A, Grygo SB, Sun Z, Pitel KS, Lingle WL, Goetz MP, Ingle JN, Spelsberg TC.

PLoS One. 2013;8(1):e54613. doi: 10.1371/journal.pone.0054613. Epub 2013 Jan 28.

PMID:
23382923
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Functional polymorphisms in xenobiotic metabolizing enzymes and their impact on the therapy of breast cancer.

Vianna-Jorge R, Festa-Vasconcellos JS, Goulart-Citrangulo SM, Leite MS.

Front Genet. 2013 Jan 22;3:329. doi: 10.3389/fgene.2012.00329. eCollection 2012.

PMID:
23346096
[PubMed]
Free PMC Article
9.

The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice.

Maximov PY, Lee TM, Jordan VC.

Curr Clin Pharmacol. 2013 May;8(2):135-55. Review.

PMID:
23062036
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?

Tengström M, Mannermaa A, Kosma VM, Hirvonen A, Kataja V.

BMC Cancer. 2012 Jun 18;12:257. doi: 10.1186/1471-2407-12-257.

PMID:
22708928
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.

Gjerde J, Gandini S, Guerrieri-Gonzaga A, Haugan Moi LL, Aristarco V, Mellgren G, Decensi A, Lien EA.

Breast Cancer Res Treat. 2012 Jul;134(2):693-700. doi: 10.1007/s10549-012-2074-9. Epub 2012 May 5.

PMID:
22562123
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G; Breast International Group (BIG) 1-98 Collaborative Group.

J Natl Cancer Inst. 2012 Mar 21;104(6):441-51. doi: 10.1093/jnci/djs125. Epub 2012 Mar 6.

PMID:
22395644
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen.

Jager NG, Rosing H, Linn SC, Schellens JH, Beijnen JH.

Breast Cancer Res Treat. 2012 Jun;133(2):793-8. doi: 10.1007/s10549-012-2000-1. Epub 2012 Mar 3.

PMID:
22388692
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment.

Park HS, Choi JY, Lee MJ, Park S, Yeo CW, Lee SS, Shin JG, Park BW.

J Korean Med Sci. 2011 Aug;26(8):1007-13. doi: 10.3346/jkms.2011.26.8.1007. Epub 2011 Jul 27.

PMID:
21860550
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.

Irvin WJ Jr, Walko CM, Weck KE, Ibrahim JG, Chiu WK, Dees EC, Moore SG, Olajide OA, Graham ML, Canale ST, Raab RE, Corso SW, Peppercorn JM, Anderson SM, Friedman KJ, Ogburn ET, Desta Z, Flockhart DA, McLeod HL, Evans JP, Carey LA.

J Clin Oncol. 2011 Aug 20;29(24):3232-9. doi: 10.1200/JCO.2010.31.4427. Epub 2011 Jul 18.

PMID:
21768473
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors.

Ahern TP, Christensen M, Cronin-Fenton DP, Lunetta KL, Søiland H, Gjerde J, Garne JP, Rosenberg CL, Silliman RA, Sørensen HT, Lash TL, Hamilton-Dutoit S.

Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1937-43. doi: 10.1158/1055-9965.EPI-11-0419. Epub 2011 Jul 12.

PMID:
21750172
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.

Cronin-Fenton DP, Lash TL.

Expert Rev Clin Pharmacol. 2011 May;4(3):363-77. doi: 10.1586/ecp.11.18. Review.

PMID:
21709817
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, Garne JP, Sørensen HT, Hellberg Y, Christensen M, Pedersen L, Hamilton-Dutoit S.

J Natl Cancer Inst. 2011 Mar 16;103(6):489-500. doi: 10.1093/jnci/djr010. Epub 2011 Feb 15.

PMID:
21325141
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Coprescription of tamoxifen and medications that inhibit CYP2D6.

Sideras K, Ingle JN, Ames MM, Loprinzi CL, Mrazek DP, Black JL, Weinshilboum RM, Hawse JR, Spelsberg TC, Goetz MP.

J Clin Oncol. 2010 Jun 1;28(16):2768-76. doi: 10.1200/JCO.2009.23.8931. Epub 2010 May 3. Review. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543.

PMID:
20439629
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Ramírez J, Ratain MJ, Innocenti F.

Future Oncol. 2010 Apr;6(4):563-85. doi: 10.2217/fon.10.17. Review.

PMID:
20373870
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk